(Q36818242)

16 August 2017

title

Lipid-lowering therapy and outcomes in heart failure (English)

1 reference

16 August 2017

Jacob A Udell

3

0 references

Colleen M Norris

object named as

Colleen M Norris

2

0 references

author name string

Joel G Ray

1

1 reference

16 August 2017

Ross T Tsuyuki

4

1 reference

16 August 2017

Finlay A McAlister

5

1 reference

16 August 2017

Merril L Knudtson

6

1 reference

16 August 2017

William A Ghali

7

1 reference

16 August 2017

publication date

1 March 2007

1 reference

Journal of Cardiovascular Pharmacology and Therapeutics

16 August 2017

published in

1 reference

16 August 2017

volume

12

1 reference

16 August 2017

issue

1

1 reference

16 August 2017

page(s)

27-35

1 reference

Chronic heart failure in the United States: a manifestation of coronary artery disease

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Incidence and aetiology of heart failure; a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Beneficial effects of statins in patients with non-ischemic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Use of statins and the subsequent development of deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Sex differences in access to coronary revascularization after cardiac catheterization: importance of detailed clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

The central role of the propensity score in observational studies for causal effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Revascularization in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Frailty predicts long-term mortality in elderly subjects with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Digital subtraction intravenous left ventricular angiography: Comparison with conventional intraventricular angiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Frequency of congestive heart failure in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Statin therapy is associated with lower mortality among patients with severe heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Statins and mortality among elderly patients hospitalized with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Primary and secondary prevention of heart failure with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Rationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1074248407299839

21 January 2018

Identifiers

DOI

10.1177/1074248407299839

1 reference

16 August 2017

1 reference